Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNFα and suppression of NF-κB activities

Abstract

Mechanisms underlying radiation and chemotherapy resistance, the hallmark of human melanoma, are not well understood. Here we demonstrate that expression levels of signal adaptor protein TRAF2 coincide with melanoma resistance to UV-irradiation. Altered TRAF2 signaling by a form of TRAF2, which lacks the ring finger domain (TRAF2ΔN), increases activities of p38 MAPK, ATF2, and the level of TNFα expression. Forced expression of TRAF2ΔN in HHMSX highly metastatic melanoma cells that lack Fas expression and thus utilize the TNFα-TNFR1 as the major apoptotic pathway sensitized cells to UV-induced apoptosis. An over twofold increase in degree of apoptosis was observed in TRAF2ΔN expressing cells that were treated with actinomycin D, anisomycin or with the radiomimetic drug neocarzinostatin. Sensitization by TRAF2ΔN is selective since it was not observed in response to either Taxol or cis-platinum treatment. TRAF2ΔN effects are primarily mediated via p38 since inhibition of p38 reduces, whereas activation of p38 promotes the level of UV-induced apoptosis. Conversely, activation of IKK attenuates the sensitization of melanoma by TRAF2ΔN, indicating that p38-mediated suppression of NF-κB activity is among TRAF2ΔN effects. Our finding identifies p38, TNFα and NF-κB among key players that efficiently sensitizes melanoma cells to UV-, ribotoxic (anisomycin) and radiomimetic chemicals-induced programmed cell death in response to aberrant TRAF2 signaling.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Abbreviations

AP1:

activator protein-1

ATF2:

activating transcription factor 2

NF-κB:

nuclear factor kappa B

IKK:

inhibitor nuclear factor kappa B kinase

PI:

propidium iodide

TNFα:

tumor necrosis factor alpha

TNFR:

tumor necrosis factor receptor

TRAF2:

tumor necrosis factor receptor associated factor 2

GFP:

green fluorescent protein

IκB:

inhibitor NF-κB

MAPK:

mitogen-activated protein kinase

MFI:

medium fluorescence intensity

MKK:

MAPK kinase

CHX:

cycloheximide

NCS:

neocarzinostatin

References

  • Arch RH, Gedrich RW, Thompson CB . 1998 Genes Dev. 12: 2821–2830

  • Ashkenazi A, Dixit VM . 1998 Science 281: 1305–1308

  • Bakker TR, Reed D, Renno T, Jongeneel CV . 1999 Int. J. Cancer 80: 320–323

  • Deak JC, Cross JV, Lewis M, Qian Y, Parrott LA, Distelhorst CW, Templeton DJ . 1998 Proc. Natl. Acad. Sci. USA 95: 5595–6000

  • Deveraux Q, Reed JC . 1999 Genes Dev. 13: 239–252

  • Faris M, Latinis KM, Kempiak SJ, Koretzky GA, Nel A . 1998 Mol. Cell. Biol. 18: 5414–5424

  • Fuchs SY, Adler V, Pincus MR, Ronai Z . 1998 Proc. Natl. Acad. Sci. USA 95: 10541–10546

  • Fuchs SY, Chen A, Xiong Y, Pan ZQ, Ronai Z . 1999 Oncogene 18: 2039–2046

  • Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC . 1998 J. Biol. Chem. 273: 34120–34127

  • Goillot E, Raingeaud J, Ranger A, Tepper RI, Davis RJ, Harlow E, Sanchez I . 1997 Proc. Natl. Acad. Sci. USA 94: 3302–3307

  • Hsu H, Shu HB, Pan MG, Goeddel DV . 1996 Cell 84: 299–308

  • Ip YT, Davis RJ . 1998 Curr. Opinions Cell Biol. 10: 205–219

  • Ivanov VN, Ronai Z . 1999 J. Biol. Chem. 274: 14079–14089

  • Ivanov VN, Ronai Z . 2000 Oncogene 19: 3003–3012

  • Ivanov VN, Kherl JH, Ronai Z . 2000 Oncogene 19: 933–942

  • Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR . 1998 Mol. Cell 1: 551

  • Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P . 1998 Immunity 8: 297–303

  • Krammer PH . 2000 Nature 407: 789–795

  • Lin, X, Mu Y, Cunningham ET, Marcu KB, Geleziunas R, Greene WC . 1998 Mol. Cell Biol. 18: 5899–5907

  • Liu ZG, Hsu H, Goeddel DV, Karin M . 1996 Cell 87: 565–576

  • Malinin NL, Boldin MP, Kovalenko AV, Wallach D . 1997 Nature 385: 540–544

  • Maniatis T . 1999 Genes Dev. 13: 505–510

  • Meier F, Satyamoorthy K, Nesbit M, Hsu MY, Schittek B, Garbe C, Herlyn M . 1998 Bioscience 3: d1005–d1010

  • Minden A, Karin M . 1997 Biochim. Biophys. Acta. 1333: F85–F104

  • Moretti S, Pinzi C, Spallazani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C, Herlyn M . 1999 Int. J. Cancer 20: 160–168

  • Nagata S . 1997 Cell 88: 355–365

  • Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, Levrero M . 1997 Science 275: 200–203

  • Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . 1991 J. Immunol. Methods 139: 271–279

  • Nishitoh H, Saitoh M, Mochida Y, Takeda K, Nakano H, Rothe M, Miyazono K, Ichijo H . 1998 Mol. Cell 2: 389–395

  • Peixoto JG, Andreo P . 2000 Phys. Med. Biol. 45: 563–575

  • Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E, Tschopp J . 1999 EMBO J. 18: 1824–1831

  • Relaix F, Wei XJ, Wu X, Sassoon DA . 1998 Nature Genetics 18: 287–291

  • Rhoades KL, Golub SH, Economou JS . 1992 J. Biol. Chem. 267: 22102–22107

  • Ronai Z, Yang YM, Fuchs SY, Adler V, Sardana M, Herlyn M . 1998 Oncogene 16: 523–531

  • Ruller S, Stahl C, Kohler G, Eickhoff B, Breder J, Schlaak M, van der Bosch J . 1999 Clin. Cancer Res. 10: 2714–2725

  • Song HY, Regnier CH, Kirschning CJ, Goeddel DV, Rothe M . 1997 Proc. Natl. Acad. Sci. USA 94: 9792–9796

  • Tan P, Fuchs SY, Chen A, Wu K, Gomez C, Ronai Z, Pan ZQ . 1999 Mol. Cell 3: 527–533

  • Tobin D, van Hogerlinden M, Toftgard R . 1998 Proc. Natl. Acad. Sci. USA 95: 565–569

  • Tyers M, Jorgensen P . 2000 Curr. Opin. Genet. Dev. in press

  • Tyers M, Willams AR . 1999 Science 284: 603–604

  • van Dam H, Huguier S, Kooistra K, Baguet J, Vial E, van der Eb AJ, Herrlich P, Angel P, Castellazzi M . 1998 Genes Dev. 12: 1227–1239

  • Yang X, Khosravi-Far R, Chang HY, Baltimore D . 1997 Cell 89: 1067–1076

  • Yang YM, Dolan L, Ronai Z . 1996 Oncogene 12: 2223–2233

  • Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, de la Pompa JL, Ferrick D, Hum B, Iscove N, Ohashi P, Rothe M, Goeddel DV, Mak TW . 1997 Immunity 7: 715–725

  • Yuasa T, Ohno S, Kehrl JH, Kyriakis JM . 1998 J. Biol. Chem. 273: 22681–22692

  • Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M . 1997 Cell 91: 243–252

Download references

Acknowledgements

We thank Drs H van Dam, JS Economou, M Karin and R Davis for providing expression vectors and Dr M Herlyn for LU1205 and WM1552 melanoma cells. Support from the National Cancer Institute through grant CA 51995 (to Z Ronai) is gratefully acknowledged.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ivanov, V., Fodstad, Ø. & Ronai, Z. Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNFα and suppression of NF-κB activities. Oncogene 20, 2243–2253 (2001). https://doi.org/10.1038/sj.onc.1204314

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204314

Keywords

This article is cited by

Search

Quick links